Korro Bio, Inc. Common Stock (KRRO)

Korro Bio, a clinical-stage biopharmaceutical company, announced that the FDA has granted orphan drug designation to its investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 is currently being evaluated in a Phase 1/2a clinical study, and the company expects to report interim data in the second half of 2025.

The article discusses four biotech companies leveraging AI and machine learning technology to improve drug discovery and development processes. These companies are Absci, Firefly Neuroscience, Korro Bio, and NeuroSense Therapeutics.

Novo Nordisk and Korro Bio announced a $530 million drug development collaboration, but this is not seen as a threat to Moderna as the companies are working on different approaches to mRNA technology.

The average of price targets set by Wall Street analysts indicates a potential upside of 86.9% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday. Shares of Ecolab Inc. (NYSE: ECL) rose during Tuesday’s session after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS guidance above estimates. Ecolab posted adjusted earnings of $1.55 per share, beating market estimates of $1.54 per share. The company’s quarterly sales came in at $3.94 billion versus estimates of $3.93 billion, according to data from Benzinga Pro. Ecolab shares gained 6.4% to $216.00 on Tuesday. Here are some other big stocks recording gains in today’s session. Whole Earth Brands, Inc. (NASDAQ: FREE) gained 35.3% to $4.75. Whole Earth Brands signed a definitive agreement to be acquired by affiliates of Sababa Holdings FREE, LLC for $4.875 per share in ...